GlaxoSmithKline), a pleuromutilin approved in 2008; and tigecycline (Tygacil; Pfizer), a next-generation tetracycline approved in 2005. The reasons behind the decline in antibiotic research and ...

GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Service Income and Other Operating Revenue for the year ending 31-Mar-2024.For the quarter ended 31-12-2024, ...

Bonus Aug 17, 1998 Sep 20, 1998 Aug 10, 1998 Bonus Ratio: 1 share(s) for every 1 shares held Rights--Feb 02, 1994 Rights ratio: 1 share for every 10 held at a price of Rs 15.0 Bonus--Jun 22, 1988 ...